X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA VENUS REMEDIES SHASUN PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 123.9 -3.8 - View Chart
P/BV x 8.5 0.1 5,972.8% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
VENUS REMEDIES
Mar-18
SHASUN PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs94126 74.8%   
Low Rs4661 74.6%   
Sales per share (Unadj.) Rs214.2301.8 71.0%  
Earnings per share (Unadj.) Rs5.3-24.9 -21.5%  
Cash flow per share (Unadj.) Rs15.82.5 621.7%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3293.3 18.2%  
Shares outstanding (eoy) m56.6212.34 458.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 105.3%   
Avg P/E ratio x13.1-3.8 -348.4%  
P/CF ratio (eoy) x4.436.7 12.0%  
Price / Book Value ratio x1.30.3 411.0%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9581,154 343.0%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m2,164393 550.4%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m12,1273,724 325.6%  
Other income Rs m22923 1,019.3%   
Total revenues Rs m12,3563,747 329.8%   
Gross profit Rs m1,009395 255.6%  
Depreciation Rs m594338 175.5%   
Interest Rs m415354 117.2%   
Profit before tax Rs m230-275 -83.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-7332 -230.1%   
Profit after tax Rs m302-307 -98.4%  
Gross profit margin %8.310.6 78.5%  
Effective tax rate %-31.7-11.5 275.8%   
Net profit margin %2.5-8.2 -30.2%  
BALANCE SHEET DATA
Current assets Rs m6,8842,638 261.0%   
Current liabilities Rs m8,4562,305 366.9%   
Net working cap to sales %-13.08.9 -144.9%  
Current ratio x0.81.1 71.1%  
Inventory Days Days62135 45.5%  
Debtors Days Days10846 232.1%  
Net fixed assets Rs m4,9704,871 102.0%   
Share capital Rs m113123 91.8%   
"Free" reserves Rs m2,8753,496 82.2%   
Net worth Rs m3,0203,619 83.5%   
Long term debt Rs m1,8171,374 132.2%   
Total assets Rs m13,3477,509 177.8%  
Interest coverage x1.60.2 696.7%   
Debt to equity ratio x0.60.4 158.5%  
Sales to assets ratio x0.90.5 183.2%   
Return on assets %5.40.6 851.2%  
Return on equity %10.0-8.5 -118.0%  
Return on capital %13.31.6 842.1%  
Exports to sales %46.40-   
Imports to sales %14.213.9 102.7%   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728517 334.5%   
Fx inflow Rs m5,8430-   
Fx outflow Rs m2,173517 420.7%   
Net fx Rs m3,669-517 -710.5%   
CASH FLOW
From Operations Rs m398514 77.3%  
From Investments Rs m-1,635-123 1,328.2%  
From Financial Activity Rs m1,309-387 -338.1%  
Net Cashflow Rs m714 1,695.2%  

Share Holding

Indian Promoters % 39.2 32.9 119.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.2 2,000.0%  
FIIs % 17.6 0.6 3,034.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 66.4 59.6%  
Shareholders   20,750 20,121 103.1%  
Pledged promoter(s) holding % 12.3 36.4 33.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS